×
Back to Agenda
The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs
Session Chair(s)
Lindsey Murray, PhD, MPH
Executive Director, Rare Disease COA Consortium, Critical Path Institute, United States
Appropriate endpoint selection for rare disease trials is challenging. The Rare Disease Clinical Outcome Assessment (COA) Consortium’s aim is the creation of a resource of publicly available COAs deemed fit-for-purpose as trial endpoint measures.
Learning Objective : Explain a definition of “rare disease” and describe the global burden of rare diseases and the challenges to drug development; Describe the unmet need that the Rare Disease Clinical Outcome Assessment Consortium is intended to address. •Discuss why a pre-competitive, multi-stakeholder collaboration is the optimal setting for achieving its aim of creating a database of publicly available COAs.
Speaker(s)
Michelle Campbell, PhD
Associate Director, Stakeholder Engagement and Clinical Outcomes, ON, OND, CDER, FDA, United States
Panelist
Stephen Joel Coons, PhD
Senior Advisor, Critical Path Institute, United States
Panelist
Vanessa Boulanger, MSc
Director of Research Programs, National Organization for Rare Disorders (NORD), United States
Panelist
Dylan Trundell, MSc
Senior Principal PCOR Scientist, Roche Products Ltd., United Kingdom
Panelist
Have an account?